Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | PAN domain-containing protein | 0.0342 | 0.4388 | 0.5 |
Schistosoma mansoni | apoptosis regulator bax | 0.0056 | 0 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.0342 | 0.4388 | 0.5 |
Schistosoma mansoni | bcl-2 homologous antagonist/killer (bak) | 0.0056 | 0 | 0.5 |
Brugia malayi | Apoptosis regulator proteins, Bcl-2 family protein | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Loa Loa (eye worm) | apoptosis regulator protein | 0.0056 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0056 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0056 | 0 | 0.5 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.0707 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC80 (functional) | = 64 ug ml-1 | Antifungal activity against Cryptococcus neoformans after 72 hrs by serial dilution method | ChEMBL. | 25115626 |
MIC80 (functional) | > 64 ug ml-1 | Antifungal activity against Candida albicans after 24 hrs by serial dilution method | ChEMBL. | 25115626 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.